Tempus xG—Hereditary Cancer Testing

A complete picture of your patient’s cancer may also include their hereditary risk.

We offer a comprehensive approach, providing both germline and somatic testing, all on one platform.

Contact us

Hereditary Cancer Germline Testing Portfolio (Powered by GeneDx)

Tempus xG+
(extended hereditary cancers)

88 gene multi-cancer panel
Covers genes associated with both common and rare hereditary cancer syndromes

Download xG+ Gene List & Technical Specifications

Tempus xG
(common hereditary cancers)

52 gene common hereditary cancers panel
Covers genes associated with six of the most common hereditary cancer types (breast, ovarian, colorectal, endometrial, prostate, and pancreatic)

Download xG Gene List & Technical Specifications

Our Differentiators

  • One platform

    to order somatic and germline tests with reports delivered in the Tempus Hub

  • Concurrent & standalone

    options for ordering germline panels

  • Confirmatory germline testing

    or incidental germline findings identified on our somatic reports (see more details below)

  • One financial assistance program

    that covers all tests

  • Connecting clinicians

    by providing access to one platform to help ensure patients are tested in a timely manner

We are one of the first commercial labs to offer incidental germline and confirmatory testing on one platform. For more information on incidental germline and confirmatory testing see FAQ below.

  1. Identification of Incidental Germline Findings

    Patient’s xT tumor/normal matched testing identifies one or more germline variants in the normal sample.

    These are included as incidental germline findings on the patient’s xT report.

  2. Confirmatory Germline Testing

    Patient qualifies for germline testing based on incidental germline finding.

    xG or xG+ provides confirmation of incidental germline findings through validated germline testing.

  3. Patient Impact

    Provides the opportunity for confirmatory testing in patients who may not otherwise qualify for germline testing based on age, family history, or tumor type.

    Allows for identification of additional hereditary cancer risk for the patient and at-risk relatives.

View Frequently Asked Questions

What are incidental germling findings?

Tempus sequences a normal match sample alongside the tumor sample for our xT assay and issues incidental germline findings in 65 hereditary cancer genes. The incidental germline component of xT may have implications for both the patient and family members, however, validated germline testing is required to confirm these incidental findings.

Do our germline offerings provide confirmatory testing?

xG+ and xG are validated germline assays that may be used to confirm incidental germline findings reported on xT tumor/normal matched sequencing or potential germline findings detected by xT tumor only sequencing or xF liquid biopsy.

Are there other clinical indications for confirmatory testing?

xG+ and xG may also be used to test for Lynch syndrome mutations for any MSI-High tumors.

When should hereditary cancer testing be considered?

For patients with a personal history of cancer:

  • Early age at diagnosis (<50y)
  • Ovarian, pancreatic, or metastatic/high-grade prostate cancer diagnosed at any age
  • Rare tumors/cancers diagnosed at any age, including male breast cancer, paragangliomas, pheochromocytomas, medullary thyroid cancer, etc.
  • Multiple primary cancers or bilateral tumors
  • Ashkenazi Jewish ancestry
  • Tumor testing indicative of an underlying germline mutation/hereditary cancer syndrome:
    • Incidental germline finding
    • MSI-High or dMMR tumors

For patients with a family history of cancer:

  • Multiple relatives on the same side of the family with the same or related types of cancers:
    • Breast, ovarian, pancreatic and/or prostate
    • Colorectal, endometrial, and/or gastric
  • Germline variant associated with increased cancer risk identified in another blood relative

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL; Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70-87. doi:10.1038/gim.2014.147

National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2022). https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503. Accessed February 3, 2022.

National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal (Version 1.2021). https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1436. Accessed February 3, 2022.

Which cancer types are covered by xG?

xG includes genes associated with breast, ovarian, colorectal, endometrial, prostate, and pancreatic cancers.

Which rare hereditary cancer types are covered by xG+?

In addition to the common hereditary cancers, xG+ covers an array of genes associated with rare hereditary tumor types including: renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, select pediatric tumors, select hematologic malignancies

Which genes are included on each panel?

xG+ (extended hereditary cancers) Gene List (88 genes):

AIP, ALK, ANKRD26, APC*, ATM*, AXIN2*, BAP1*, BARD1*, BLM*, BMPR1A*, BRCA1*, BRCA2*, BRIP1*, CDC73, CDH1*, CDK4*, CDKN1B, CDKN2A*, CEBPA*, CHEK2*, CTNNA1, DDX41, DICER1*, EPCAM*, ETV6*, FANCC, FANCM, FH*, FLCN*, GATA2*, GALNT12, GREM1, HOXB13, KIT*, LZTR1, MAX*, MEN1*, MET*, MITF, MLH1*, MSH2*, MSH3*, MSH6*, MUTYH*, NBN*, NF1*, NF2*, NTHL1*, PALB2*, PDGFRA*, PHOX2B*, PMS2*, POLD1*, POLE*, POT1, PRKAR1A*, PTCH1*, PTEN*, RAD51C*, RAD51D*, RB1*, RECQL, RET*, RNF43, RPS20, RUNX1*, SAMD9, SAMD9L, SDHA*, SDHAF2*, SDHB*, SDHC*, SDHD*, SMAD4*, SMARCA4*, SMARCB1*, SMARCE1, SRP72, STK11*, SUFU*, TERC, TERT, TMEM127*, TP53*, TSC1*, TSC2*, VHL*, WT1*

*Included on xT Germline Incidental Findings List (see xT disclaimers for reporting limitations)

xG (common hereditary cancers) Gene List (52 genes):

APC*, ATM*, AXIN2*, BAP1, BARD1, BLM, BMPR1A*, BRCA1*, BRCA2*, BRIP1*, CDH1*, CDK4, CDKN2A*, CHEK2*, EPCAM*, FANCC, FANCM, FH*, FLCN*, GALNT12, GREM1 (SCG5), HOXB13, MET, MITF, MLH1*, MSH2*, MSH3*, MSH6*, MUTYH*, NBN*, NF1, NTHL1, PALB2*, PMS2*, POLD1*, POLE*, POT1, PTEN*, RAD51C*, RAD51D*, RECQL, RNF43, RPS20, SDHB*, SDHC*, SDHD*, SMAD4*, STK11*, TP53*. TSC1*, TSC2*, VHL*

*Included on xT Germline Incidental Findings List (see xT disclaimers for reporting limitations)

How can I order a test?

Order can be placed via the Tempus requisition form or through the Tempus Hub. You can find a detailed outline of our process through our ordering process walk-through guide.

Is familial variant testing available for my patients?

Familial variant testing (FVT) is available for at-risk relatives (out to third degree) at no additional cost within 90 days of proband’s xG/xG+ report.

Outside of the 90 day window, FVT is available through a $99 Self Pay option or billable to insurance.

Orders for familial variant testing can be placed through this form.

My practice does not have access to a genetic counselor; do you provide genetic counseling services?

Patient genetic counseling services are available through our partner, MyGeneTeam. To request a genetic counseling consultation for your patient, please submit a completed referral form to support@tempus.com.

Download form

Download MyGeneTeam Patient Information Sheet

Does Tempus provide amended reports for variant reclassifications?

Yes, amended reports are provided in the Tempus HUB for any variant reclassifications. Providers will be notified if an amended report is issued for any reason.

Germline and somatic testing on one comprehensive platform

This is the future of healthcare.